Obinutuzumab

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1217 publications

Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy.

Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy.

Journal: The New England journal of medicine

Published: June 05, 2026

From clinical to immunologic remission in lupus nephritis: Toward MRD-grade B-cell depletion.

From clinical to immunologic remission in lupus nephritis: Toward MRD-grade B-cell depletion.

Journal: Lupus

Published: June 03, 2026

Anti-Obinutuzumab Antibodies in Primary Membranous Nephropathy.

Anti-Obinutuzumab Antibodies in Primary Membranous Nephropathy.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: May 19, 2026

ANCA vasculitis: what is in the pipeline.

ANCA vasculitis: what is in the pipeline.

Journal: Current opinion in nephrology and hypertension

Published: May 14, 2026

Comparative Analysis of Lupus Nephritis Guidelines: ACR 2025, EULAR 2025, and Kdigo 2024.

Comparative Analysis of Lupus Nephritis Guidelines: ACR 2025, EULAR 2025, and Kdigo 2024.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: May 08, 2026

Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease.

Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 30, 2026

HSR26-228: BTK Inhibitor (Bruton Tyrosine Kinase Inhibitor) Plus Anti-CD20 Antibody Therapy Surpasses CIT (Chemoimmunotherapy) in Frontline CLL (Chronic Lymphocytic Leukemia) With Obinutuzumab Drives Deeper Remissions: A Meta-Analysis of Randomized Controlled Trials.

HSR26-228: BTK Inhibitor (Bruton Tyrosine Kinase Inhibitor) Plus Anti-CD20 Antibody Therapy Surpasses CIT (Chemoimmunotherapy) in Frontline CLL (Chronic Lymphocytic Leukemia) With Obinutuzumab Drives Deeper Remissions: A Meta-Analysis of Randomized Controlled Trials.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 29, 2026

The Inverted Pyramid Approach: Early Combination Therapy With Voclosporin and Obinutuzumab in Active Lupus Nephritis.

The Inverted Pyramid Approach: Early Combination Therapy With Voclosporin and Obinutuzumab in Active Lupus Nephritis.

Journal: Cureus

Published: April 22, 2026

CLO26-111: Treatment-Naïve CLL in Routine Care: Acalabrutinib Monotherapy Versus Acalabrutinib Plus Obinutuzumab.

CLO26-111: Treatment-Naïve CLL in Routine Care: Acalabrutinib Monotherapy Versus Acalabrutinib Plus Obinutuzumab.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 16, 2026

Impact of afucosylation strategy on antibody function: a comparative study of glycoengineered anti-CD20 antibodies Obinutuzumab and Obinutuzumab beta.

Impact of afucosylation strategy on antibody function: a comparative study of glycoengineered anti-CD20 antibodies Obinutuzumab and Obinutuzumab beta.

Journal: mAbs

Published: April 13, 2026

Is Obinutuzumab the Answer to Primary Membranous Nephropathy Resistant to Rituximab?

Is Obinutuzumab the Answer to Primary Membranous Nephropathy Resistant to Rituximab?

Journal: Kidney international reports

Published: April 08, 2026

Positive results for obinutuzumab in SLE phase III trial.

Positive results for obinutuzumab in SLE phase III trial.

Journal: Nature reviews. Rheumatology

Published: April 08, 2026

Showing 1-12 of 1,217

Last Updated: 06/30/2026